Home/Pipeline/Bicycle Toxin Conjugates (BTCs)

Bicycle Toxin Conjugates (BTCs)

Various Solid Tumors

Discovery/PreclinicalActive

Key Facts

Indication

Various Solid Tumors

Phase

Discovery/Preclinical

Status

Active

Company

Bicycle Therapeutics

About Bicycle Therapeutics

Bicycle Therapeutics is a UK-based, NASDAQ-listed biotech pioneering a novel class of synthetic, constrained peptide therapeutics. Its core Bicycle® platform generates molecules designed to deliver the high specificity of biologics with the favorable pharmacokinetics of small molecules, enabling deep tissue penetration in solid tumors. The company has advanced multiple wholly-owned and partnered programs into clinical development, focusing on oncology targets like Nectin-4 and EphA2, while actively exploring partnerships to expand into other therapeutic areas. Its strategy is to build a leading solid tumor medicine portfolio, validated by clinical data and strategic collaborations.

View full company profile

Therapeutic Areas

Oncology Immuno-oncology

Other Various Solid Tumors Drugs

Drug	Company	Phase	Status
NUC-8232	NuCana	Phase 1	Active
TCR Library Program	Medigene	Discovery	Active
Guardant Infinity Biomarker Discovery	Guardant Health	Development/Commercial	Active
Cytotoxic Oncology Generic	MSN Laboratories	Pre‑clinical	Active
APCEDEN®	APAC Biotech	Approved	Commercial
Solid Tumor Profiling	Diatech Pharmacogenetics	Commercial	Active
BAVENCIO (avelumab)	EMD Serono	Approved	Active (Lifecycle Management)
FoundationOne®CDx Indication Expansion	Foundation Medicine	Approved/Commercial	Active
FoundationOne®Liquid CDx Indication Expansion	Foundation Medicine	Approved/Commercial	Active
177Lu‑BetaBart (RV‑01)	AtomVie Global Radiopharma	Phase 1/2a	Active
BeiGene Oncology Portfolio	EVA Pharma	Phase 2/3	Active
Bevacizumab Biosimilar	Bio Usawa Biotechnology	Preclinical	Active